ATE483470T1 - Verfahren zur expansion tumorreaktiver t- lymphozyten zur immuntherapie von patienten mit krebs - Google Patents

Verfahren zur expansion tumorreaktiver t- lymphozyten zur immuntherapie von patienten mit krebs

Info

Publication number: ATE483470T1
Authority: AT; Austria
Prior art keywords: lymphocytes; reactive; tumour; helper; phase
Prior art date: 2005-12-21

Application number

AT06841050T

Other languages

English (en)

Inventor

Ola Winqvist

Magnus Thoern

Original Assignee

Sentoclone Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-21

Filing date

2006-12-20

Publication date

2010-10-15

2006-12-20 Application filed by Sentoclone Ab filed Critical Sentoclone Ab

2006-12-20 Priority claimed from PCT/EP2006/012304 external-priority patent/WO2007071388A1/en

2010-10-15 Application granted granted Critical

2010-10-15 Publication of ATE483470T1 publication Critical patent/ATE483470T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 10
210000001744 T-lymphocyte Anatomy 0.000 title abstract 8
238000000034 method Methods 0.000 title abstract 4
201000011510 cancer Diseases 0.000 title abstract 2
238000009169 immunotherapy Methods 0.000 title 1
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 abstract 1
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 abstract 1
108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 1
102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 1
102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 abstract 1
230000003213 activating effect Effects 0.000 abstract 1
230000004913 activation Effects 0.000 abstract 1
230000001270 agonistic effect Effects 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
239000002458 cell surface marker Substances 0.000 abstract 1
108040006849 interleukin-2 receptor activity proteins Proteins 0.000 abstract 1
210000004698 lymphocyte Anatomy 0.000 abstract 1
239000003550 marker Substances 0.000 abstract 1
230000001737 promoting effect Effects 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
230000004083 survival effect Effects 0.000 abstract 1

Landscapes

Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT06841050T 2005-12-21 2006-12-20 Verfahren zur expansion tumorreaktiver t- lymphozyten zur immuntherapie von patienten mit krebs ATE483470T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US75282805P	2005-12-21	2005-12-21
DKPA200501810		2005-12-21
PCT/EP2006/012304 WO2007071388A1 (en)	2005-12-21	2006-12-20	Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer

Publications (1)

Publication Number	Publication Date
ATE483470T1 true ATE483470T1 (de)	2010-10-15

Family

ID=36763835

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06841050T ATE483470T1 (de)	2005-12-21	2006-12-20	Verfahren zur expansion tumorreaktiver t- lymphozyten zur immuntherapie von patienten mit krebs

Country Status (5)

Country	Link
CN (1)	CN101346463B (de)
AT (1)	ATE483470T1 (de)
BR (1)	BRPI0620187A2 (de)
DE (1)	DE602006017435D1 (de)
NZ (1)	NZ569105A (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015100495A1 (en) *	2014-01-03	2015-07-09	FullHope Biomedical Co., Ltd.	Modified natural killer cells, compositions and uses thereof
ES2738705T3 (es) *	2014-09-19	2020-01-24	Hope City	Linfocitos T de receptor de antígeno quimérico coestimulante que se dirigen a IL13R 2
GB201519340D0 (en) *	2015-11-02	2015-12-16	Cambridge Entpr Ltd	Methods of T-lymphocyte expansion
CN105586312A (zh) *	2016-02-29	2016-05-18	时宏珍	Hla-a0201限制性抗muc-1抗原特异性ctl的制备方法
SG11201900442PA (en) *	2016-07-21	2019-02-27	Berkeley Lights Inc	Sorting of t lymphocytes in a microfluidic device
CN106754703B (zh) *	2016-12-26	2018-03-16	浙江丹晖生物科技有限公司	一种til细胞体外扩增培养基组合和培养方法
US11293924B2 (en) *	2017-02-07	2022-04-05	Saitama Medical University	Immunological biomarker for predicting clinical effect of cancer
JP7606225B2 (ja)	2019-02-20	2024-12-25	学校法人埼玉医科大学	放射線治療による抗腫瘍免疫効果を評価する末梢血バイオマーカー

2006
- 2006-12-20 AT AT06841050T patent/ATE483470T1/de not_active IP Right Cessation
- 2006-12-20 CN CN2006800487393A patent/CN101346463B/zh active Active
- 2006-12-20 DE DE602006017435T patent/DE602006017435D1/de active Active
- 2006-12-20 NZ NZ569105A patent/NZ569105A/en not_active IP Right Cessation
- 2006-12-20 BR BRPI0620187-3A patent/BRPI0620187A2/pt not_active IP Right Cessation

Also Published As

Publication number	Publication date
BRPI0620187A2 (pt)	2011-11-01
CN101346463A (zh)	2009-01-14
NZ569105A (en)	2011-07-29
DE602006017435D1 (de)	2010-11-18
CN101346463B (zh)	2012-06-13

Similar Documents

Publication	Publication Date	Title
Kyrysyuk et al.	2023	Designing cancer immunotherapies that engage T cells and NK cells
Gao et al.	2007	Contrasting effects of cyclosporine and rapamycin in de novo generation of alloantigen‐specific regulatory T cells
Ilander et al.	2014	Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy
Liyanage et al.	2006	Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma
Putnam et al.	2013	Clinical grade manufacturing of human alloantigen‐reactive regulatory T cells for use in transplantation
Donia et al.	2012	Analysis of Vδ1 T cells in clinical grade melanoma-infiltrating lymphocytes
MX2023001962A (es)	2023-04-26	Composiciones anti-cd28.
BR112021021843A8 (pt)	2022-06-21	Composições de proteínas de fusão quiméricas modificadas e método de uso das mesmas
MY202870A (en)	2024-05-27	Anti-ctla-4 antibodies and uses thereof
WO2005100399A3 (en)	2006-12-21	Dr5 antibodies and uses thereof
PE20140673A1 (es)	2014-06-14	Nuevos moduladores y metodos para su uso
EP4470547A3 (de)	2025-02-26	Rezeptoren zur gezielten costimulation für adoptive zelltherapie
WO2019160866A3 (en)	2020-05-14	Compositions and methods for tumor immunotherapy
KR20090126329A (ko)	2009-12-08	인간 혈액 유래의 ｃｄ4＋ｃｄ25＋ 조절성 ｔ 세포
WO2008033403A3 (en)	2008-07-24	Agents and methods to elicit anti-tumor immune response
MX2009008918A (es)	2009-09-14	Activacion de celulas que presentan antigeno humano a traves de clec-6.
RU2008138880A (ru)	2010-04-10	Лечение рака, комбинирующее лимфоистощающее вещество с цтл и цитокинами
BR0309254A (pt)	2005-03-01	Uso de um anticorpo anti-ctla-4
WO2006065495A3 (en)	2006-09-08	Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
MX2024010339A (es)	2024-09-30	Anticuerpos anti-cd28 x anti-psma.
RU2013107154A (ru)	2014-09-20	Способы нанесения кожного трансплантата
NZ529404A (en)	2005-10-28	A cell therapy method for the treatment of tumours
US20170298322A1 (en)	2017-10-19	Method for ex-vivo expansion of regulatory t cells with enhanced suppressive function for clinical application in immune mediated diseases
DE602005016887D1 (de)	2009-11-12	Poliersystem mit hochverzweigtem polymer
WO2023288203A3 (en)	2023-02-16	T cell receptors specific for tumor-associated antigens and methods of use thereof

Legal Events

Date	Code	Title	Description
2011-04-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties